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Abstract
Background: The incidence and survival of melanoma are increasing, but little is known about its
long-term health effects in adult survivors.
Methods: A health survey was available from 996 melanoma survivors (577 treated with surgery
alone, and 391 with combined treatments). Their medical/physiologic and psychosocial responses
were analyzed and compared with those of the survivors from other cancers.
Results: The melanoma survivors were 44.8 ± 12.8 years of age at diagnosis (significantly younger
than the survivors of other cancers) and 63.7 ± 12.8 years at survey. Melanoma survivors were less
likely to report that cancer had affected their health than survivors of other cancers (15.8% vs.
34.9%). The 577 individuals treated with surgery alone reported arthritis/osteoporosis, cataracts,
and heart problems most frequently (less often than survivors of other cancers). The 391
individuals who had undergone combined treatments reported circulation problems and kidney
problems generally as often as survivors of other cancers. Health problems were not associated
with number of decades since diagnosis but with age at diagnosis, treatment modality, and family
relationships.
Conclusion: We present information from a large cohort of long-term survivors of melanoma. As
a group, they were less likely to report that cancer had affected their overall health than survivors
of other cancers; a number of disease related and psychosocial factors appear to influence their
health profiles.
Background
The proportion of the population who consider them-
selves cancer survivors has grown in recent years and will
continue to increase, partly because of improvements in
early detection, treatment, and supportive care. The
National Cancer Institute's Office of Cancer Survivorship
reported an estimated 9.8 million cancer survivors in
2001, representing 3.5% of the nation's population [1]. At
least 14% of these cancer survivors were diagnosed more
than 20 years ago. Indeed, there is a cancer survivor in one
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of every four families in the United States. As more people
survive cancer, more attention is being given to under-
standing the long-term effects of cancer and cancer ther-
apy on the health of cancer survivors. However, research
on cancer survivorship in adults has been generally lim-
ited to conventional treatment options and their side
effects rather than the long-term outcome of survivors.
Of particular interest to us was the effect of melanoma and
its treatment on survivors, as melanoma is the sixth most
common type of cancer in American men and the seventh
most common in American women [2]. The American
Cancer Society estimated that about 59,580 new cases of
melanoma would be diagnosed in the United States dur-
ing 2005 [3]. The estimated lifetime risk in the United
States is one case in 75 people, [4] with a mean increase of
3% in new diagnoses per year [5,6]. At the same time, the
survival of patients with melanoma has improved signifi-
cantly; although 5-year and long-term survival rates vary
by disease stage at the time of diagnosis, the overall 5-year
survival for melanoma has risen to 89% [7]. Likely con-
tributing factors to this improvement are better education,
earlier detection, and more successful combination treat-
ment regimens [8]. Therefore, the number of individuals
previously diagnosed and treated for melanoma is
expected to rise significantly during the coming years.
Accordingly, it becomes increasingly important to define
what, if any, medical and psychosocial problems charac-
terize this particular group of cancer survivors. Indeed, a
major publication recently released by the Institute of
Medicine recognized the great need for systematic and
comprehensive follow-up care and analysis of cancer sur-
vivors [9].
To address the growing need for objective data analysis of
cancer survivors for their long-term sequelae, we initiated
the Life After Cancer Care at The University of Texas M. D.
Anderson Cancer Center. In the present report, we have
utilized information gathered from this program to
describe the long-term health profiles of melanoma survi-
vors.
Methods
Our data were derived from a health survey that had been
developed to collect information on the long-term health
effects of cancer and its treatment among cancer survivors,
the detailed methods of which have been published pre-
viously [10]. In brief, an intake assessment tool used by
patients of the outpatient clinics at M. D. Anderson Can-
cer Center provided the blueprint for the survey. Surveys
had been available online and had been mailed to former
M. D. Anderson patients who had been known to have
been alive more than 5 years after diagnosis and who no
longer required active treatment (as identified through
our institution's Department of Medical Informatics data-
base). Only individuals age 18 years or older were
included. We were especially interested in looking at
patients that were treated at M.D. Anderson, and because
we had previously noted significant differences between
the results of online and mailed surveys [10], we also
excluded surveys sent via our online form. In addition,
individual medical record review would only be possible
for former M.D. Anderson patients. The surveys had been
mailed to the survivors' last known addresses with a self-
addressed stamped envelope enclosed for their return.
Data were collected for 3 years. The institutional review
board at M. D. Anderson had approved this survey.
Respondents were asked to provide demographic data,
including marital status, ethnicity, education, employ-
ment, health care access, age at diagnosis, and age at the
time of the survey, and information on family and inti-
mate relationships. They were also asked if they believed
cancer had affected their overall health and were given the
opportunity to specify from a checklist the specific health
conditions or symptoms they had experienced since their
cancer treatment. The checklist specified abdominal pain,
arthritis/osteoporosis, bleeding, cataracts, circulation
problems, diabetes/sugar in the urine, dizziness, frequent
infections, hearing loss, heart problems, HIV/AIDS, kid-
ney problems, liver problems, loss of memory, lung prob-
lems, migraine headaches, psychological/psychiatric
problems, second primary cancers, seizures, skin disor-
ders, stroke, and thyroid problems. As mentioned earlier,
the checklist of health conditions were gleaned from an
intake assessment distributed to patients at M.D. Ander-
son's outpatient clinics. The survey also had specific ques-
tions about psychosocial elements such as family
relationships and employment.
The long-term health effects of cancer and its treatment on
survivors of melanoma and other cancers were compared.
In an effort to tease out the effects of cancer treatment ver-
sus effect of age in the health problems that the survivors
reported, we also compared the responses of melanoma
survivors who only had surgery versus those who also
received chemotherapy and/or radiotherapy (combined
treatments). We might expect that health problems
reported by survivors of surgery alone would tend to
reflect age more than treatment effects. We also conducted
direct medical record review of melanoma survivors who
reported that they had received combined treatments.
Data collected from the survey are stored in an Oracle
Enterprise Edition database (version 8.1.5; Oracle, Red-
wood Shores, CA), which is maintained and updated on a
regular basis by M. D. Anderson's information technology
team and the Life After Cancer Center team. Statistical
analyses were performed with Statistica for Windows (ver-
sion 6.1; StatSoft, Tulsa, OK). Frequency tabulations andBMC Cancer 2006, 6:95 http://www.biomedcentral.com/1471-2407/6/95
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histograms were used to fully describe the distribution of
responses. Descriptive statistics, including frequency, per-
centage, mean, standard deviations, median and range,
were used to summarize the survey data. Multivariate
logistic regression methods were used to simultaneously
evaluate the effects of cancer type (melanoma vs. non-
melanoma), and treatment (surgery only vs. combined
treatment) on the probability a patient believed that can-
cer had affected overall health (health affected vs. not
health affected) while controlling for age at diagnosis,
time from diagnosis, gender, marital status and ethnicity.
All statistical tests were two-sided at a significance level of
5%. All analyses were performed using SAS Version 9.1 for
Windows (SAS Institute, Cary, NC) and Statistica Version
6.1 for Windows (Tulsa, OK).
Results
Population
After three years, 11,115 surveys had been completed and
returned. We used the data collected in these surveys.
Because our focus was adult survivors of cancer, we
excluded the 387 surveys from survivors who had been
diagnosed with cancer before the age of 18 years. We
excluded 2068 surveys sent via our online form. Also
excluded were 101 surveys with incomplete data or that
did not meet all the inclusion criteria. As a result, we nar-
rowed the population to 8559 cancer survivors; of these,
996 (11.6%) had been previously diagnosed with
melanoma. The remaining 7563 were survivors of other
cancers. Of the 996 participants, 577 had undergone sur-
gery alone, and 391 had undergone combined treatment.
Twenty-eight individuals had not provided treatment
information and were excluded from the treatment analy-
sis. Figure 1 features the flowchart delineating the filtering
process. In addition, we compared the melanoma survi-
vors to the general population represented in a recent
national health survey.
The overall sample of melanoma survivors included 530
women (53.2%) and 466 men (46.8%) compared with
61.8% and 38.2%, respectively, for survivors of other can-
cers. Most (97.9%) identified themselves as white Ameri-
cans, which reflects M. D. Anderson's patient population.
The mean age at the time of diagnosis was 44.8 ± 12.8
years, which was younger than the mean age for the survi-
vors of all other cancers (49.4 ± 14.2 years) (Table 1). The
time from diagnosis to survey was 18.8 ± 8.8 years, which
was significantly longer than the interval since diagnosis
for survivors of all other cancers (15.2 ± 8.9 years). Figure
2 shows the distribution of time from diagnosis in years
for the two treatment groups. There was no significant dif-
ference by sex (data not shown). The mean age at the time
of the survey for the melanoma survivors was 63.7 ± 12.8
years. The men were older at the time of diagnosis than
the women (mean age, 47.1 ± 12.6 vs. 42.8 ± 12.6 years,
respectively). Figure 3 shows the distribution of ages at
diagnosis for the two treatment groups. Melanoma had
been diagnosed at least 5 years earlier for all (by design)
and more than 25 years earlier in 26.6% of patients who
had filled out the survey, providing information about
long-term effects.
Effects of cancer on overall health
After adjusting for cancer treatment, years from diagnosis,
and socio-demographic factors such as age at diagnosis,
gender, marital status, and race; the multivariate logistic
regression model (Table 2) indicated that non-melanoma
cancer survivors were 2.44 times (95% CI: 2.02, 2.95)
more likely to believe that cancer had affected their overall
health compared to melanoma survivors. In addition,
compared to respondents treated with surgery only, survi-
vors with combination therapy were 3.62 times (95% CI:
3.21, 4.08) were more likely to believe that cancer had
affected their overall health. Survivors generally were less
likely to believe that cancer had affected their overall
health 10–20 years (OR = 0.57; 95% CI: 0.49, 0.66) after
the time of diagnosis. Males were more likely (OR = 1.17;
95% CI: 1.05, 1.31) to believe that cancer had affected
their overall health. Compared to married survivors, wid-
owed responders were less likely (OR = 0.70; 95% CI:
1.05, 1.47) to report that their cancer had affected their
health. Finally, as age increased, patients were less likely
(OR: 0.99) to indicate that cancer had affected their over-
all health.
One hundred fifty-eight survivors (16.2%) of melanoma
believed that having had cancer had affected their overall
health compared with 2835 survivors (38.4%) of other
cancers (Table 1). These melanoma survivors were more
likely to have undergone combined treatments than sur-
gery alone (29.9% vs. 6.1%); they were more frequently
women (18.1% vs. 13.9%), and most of them had been
diagnosed more recently than had survivors of other can-
cers (16.6 ± 9.0 vs. 19.3 ± 8.7 years).
There was no difference in effect on overall health relative
to the interval since diagnosis among patients who had
been treated with surgery alone (Table 3). However, for
survivors who had undergone combined treatments, time
since diagnosis appeared to be more important; 51.3% of
those diagnosed within the previous decade said that can-
cer had affected their overall health, vs. 28.6% diagnosed
within 10–20 years and 23.1% diagnosed more than 20
years earlier.
The melanoma survivors who had reported that cancer
had affected their overall health did not differ from those
who had reported that cancer had not affected their over-
all health with respect to sex, marital status, or ethnicity
(Table 4). This was true both for those who had beenBMC Cancer 2006, 6:95 http://www.biomedcentral.com/1471-2407/6/95
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Filtering of Study Population Figure 1
Filtering of Study Population.
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treated with surgery alone and those who had undergone
combined treatments.
At the time of the survey, 504 of the respondents (50.6%)
were retired, and 327 (32.8%) reported they were still
working. There were no major differences in working sta-
tus with respect to sex, ethnicity, age at diagnosis, and
time from diagnosis to survey. Of melanoma survivors
who had undergone combined treatments, more women
reported that cancer had affected their health than men;
fewer were married in this category as well.
Long-term health effects of cancer and its treatment
Survivors had been asked to report any health problems
they had experienced since cancer treatment; the frequen-
cies of perceived health problems for melanoma survivors
treated with surgery alone or combined treatment and sur-
vivors of other cancers are outlined in Table 5.
The 577 melanoma survivors who had undergone surgery
alone generally reported fewer health problems than did
survivors of other cancers; the three most frequent symp-
toms reported were arthritis/osteoporosis (17.5%, signifi-
cantly less than survivors of other cancers), cataracts
(12.8%, similar to survivors of other cancers), and heart
problems (10.6%, less than survivors of other cancers).
The 391 melanoma survivors who had undergone com-
bined treatment were more likely to report lasting prob-
lems; the three most frequent symptoms reported were
arthritis/osteoporosis (22.5%, similar to that of survivors
Age at Diagnosis in Years Figure 3
Age at Diagnosis in Years.
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Table 1: Comparison between survivors of melanoma and other cancers on selected demographic characteristics and effect on overall 
health
Melanoma Survivors Non-Melanoma Survivors
n = 996 n = 7563
Gender
Men 466 (46.8) 2888 (38.2)
Women 530 (53.2) 4675 (61.8)
Affected health
Yes 158 (16.2) 2835 (38.4)
No 820 (83.4) 4546 (61.6)
Mean ± SD Mean ± SD
Age @ Diagnosis 44.8 ± 12.8 yrs 49.4 ± 14.2 yrs
Age @ Survey 63.7 ± 12.8 yrs 64.7 ± 13.4 yrs
Time from diagnosis 18.8 ± 8.8 yrs 15.2 ± 8.9 yrs
SD = standard deviation
Time from Diagnosis in Years Figure 2
Time from Diagnosis in Years.
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of other cancers), cataracts (15.6%, similar to that of sur-
Table 3: Influence of time since melanoma diagnosis and age at diagnosis on overall health by treatment
Combined Treatment
Total n = 384 Health Affected n = 117 Health Not affected n = 267
n (%) n (%) n (%)
Time from diagnosis
< 10 years 78 (19.9) 39 (51.3) 37 (48.7)
10–20 years 128 (32.7) 36 (28.6) 90 (71.4)
> 20 years 185 (47.3) 42 (23.1) 140 (76.9)
Mean ± SD Mean ± SD
Age at diagnosis (years) 44.7 ± 14.0 45.6 ± 12.1
Time from diagnosis (years) 16.6 ± 9.2 20.1 ± 8.4
Surgery Alone
Total n = 566 Health Affected n = 35 Health Not Affected n = 531
n (%) n (%) n (%)
Time from diagnosis
< 10 years 96 (16.6) 7 (7.4) 87 (92.6)
10–20 years 249 (43.2) 17 (7.0) 227 (93.0)
> 20 years 232 (40.2) 11 (4.8) 217 (95.2)
Mean ± SD Mean ± SD
Age at diagnosis (years) 42.4 ± 12.5 44.4 ± 12.3
Time from diagnosis (years) 16.8 ± 8.4 18.7 ± 8.7
SD = Standard deviation
Table 2: Multivariate logistic model for health affected versus non-health affected
Effect OR OR 95% Confidence Limits P-value
Type of Cancer (ref: 
Melanoma)
Non-Melanoma 2.44 2.02 2.95 <.0001
Treatment Group 
(ref: Surgery only)
Combined Therapy 3.62 3.21 4.08 <.0001
Years from Diagnosis 
(ref: <10 years)
10 – 20 yrs 0.65 0.58 0.73 0.0048
> 20 yrs 0.57 0.49 0.66 <.0001
Gender (ref: Female)
Male 1.17 1.05 1.31 0.0045
Marital (ref: Married)
Widow 0.70 0.59 0.82 <.0001
Divorced 1.25 1.05 1.47 0.0007
Never married 1.06 0.80 1.40 0.4738
Race (ref: Other)
White 0.98 0.81 1.18 0.7941
Age @ diagnosis 0.989 0.99 0.99 <.0001
OR = Odds Ratio
Ref = reference groupBMC Cancer 2006, 6:95 http://www.biomedcentral.com/1471-2407/6/95
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vivors of other cancers), and circulation problems
(15.6%, less than survivors of other cancers). The fre-
quency of self-reported heart problems in this group was
similar to those for survivors of other cancers (12.5% vs.
14.5%).
Table 5: Comparison of 10 most reported specific health problems in melanoma survivors and survivors of all other cancers
Health Problems Melanoma Survivors Survivors of all other cancers
Surgery Alone n = 577 Combined Treatments n = 391 n = 7563
Arthritis/Osteoporosis 101 (17.5%) 88 (22.5%) 2012 (26.6%)
Hearing Problems 50 (8.7%) 54 (13.8%) 892 (11.8%)
Cataracts 74 (12.8%) 61 (15.6%) 1111 (14.7%)
Circulation Problems 42 (7.3%) 61 (15.6%) 803 (10.6%)
Heart problems 61 (10.6%) 46 (12.5%) 1093 (14.5%)
Skin problems 34 (5.9%) 43 (11.0%) 415 (5.5%)
Loss of Memory 8 (1.4%) 42 (10.7%) 767 (10.1%)
Thyroid Problems 29 (5.0%) 29 (7.4%) 724 (9.6%)
Kidney Problems 32 (5.6%) 29 (7.4%) 885 (11.7%)
Abdominal Pain 14 (2.4%) 23 (5.9%) 532 (7.0%)
Table 4: Influence of demographics on overall health by treatment
Combined Treatments
Health Affected n = 117 Health Not Affected n = 267
Demographics n (%) n (%)
Sex
Male 54 (29.7) 128 (70.3)
Female 63 (31.2) 139 (68.8)
Marital status
Married 89 (31.8) 191 (68.2)
Widowed 15 (24.2) 47 (75.8)
Divorced 6 (19.4) 25 (80.7)
Never married 7 (70.0) 3 (30.0)
Ethnicity
White 117 (31.0) 260 (69.0)
Nonwhite 0 (0.0) 7 (100.0)
Surgery Alone
Health Affected n = 35 Health Not Affected n = 531
Demographics n (%) n (%)
Sex
Male 8 (3.0) 257 (97.0)
Female 27 (9.0) 274 (91.0)
Marital status
Married 24 (5.6) 404 (94.4)
Widowed 4 (5.3) 72 (94.7)
Divorced 7 (15.6) 38 (84.4)
Never married 0 (0.0) 17 (100.0)
Ethnicity
White 34 (6.1) 531 (93.9)
Nonwhite 1 (8.3) 11 (91.7)BMC Cancer 2006, 6:95 http://www.biomedcentral.com/1471-2407/6/95
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Table 6 shows the influence of treatment on 10 most fre-
quently reported long-term health problems in
melanoma survivors who had been treated with surgery
alone and combined treatment and the comparison of the
frequency of these symptoms in the two groups. The abso-
lute number of reported symptoms was small for most
categories.
Survivors that were treated with combined treatment reg-
imens complained of circulation problems, loss of mem-
ory, secondary cancers, skin problems, and abdominal
pain significantly more frequently than survivors treated
with surgery alone. Among the subgroup of melanoma
survivors who reported that cancer had affected their
health, survivors who received combined treatment com-
plained of loss of memory and secondary cancers signifi-
cantly more frequently than the survivors that were
treated with surgery alone.
We evaluated whether some of the reported symptoms
became more or less prominent over time among those
who had undergone combined treatment (Table 7).
Indeed, for the most part, there were no differences in per-
ceived health problems during the first, second, or third
decade after the diagnosis of melanoma. The only excep-
tions were cataracts and heart problems; whether this
reflects an expected influence of older age remains to be
determined.
Overall, 46.2% of survivors had reported that cancer had
improved their family relationships, 4.6% had indicated
that it had hurt their family relationships, and the remain-
ing 49.2% had said it had had no effect on their family
relationships (Table 8). The apparent effect of cancer on
family relationships did not differ in terms of sex, ethnic-
ity, age at diagnosis, age at survey, and time between sur-
vey and diagnosis. If the survivors believed that cancer
had affected their overall health, they were more likely to
report that cancer had hurt their family relationships.
Those who had undergone combined treatments were
also more likely to have reported that cancer had hurt
their intimate relationships.
Individual chart review was carried out for the 243
melanoma survivors (132 women [54.3%] and 111 men
[45.7%]) who had undergone combined treatment and
who had provided identifying information. The records
were reviewed for the types of treatment; the progress
notes of follow-up appointments (including annual fol-
low-up letters sent by the Department of Medical Infor-
matics) were scrutinized for any documentation of long-
term health effects. Metastatic disease was reported in 119
of the records (48.9%), melanoma recurrence in 47
(19.3%), and second primary cancers in 84 (34.5%).
Table 9 outlines the common treatment modalities and
the most frequent health problems reported by the survi-
vors who had undergone those treatments. Heart prob-
lems were the most frequently reported; whether this
represents a causal relationship rather than the effect of
age on the frequency of heart disease could not be
inferred.
In order to determine how health profiles of melanoma
survivors compared with those of the general U.S. popula-
tion, we compared their self-reported health conditions
with age matched responses derived from the National
Health Interview Study (NHIS) [11]. One caveat is that the
NHIS population most likely includes some cancer survi-
vors. Six health conditions in the NHIS matched to health
conditions that were included in our survey: arthritis, cat-
aracts, diabetes, hearing impairment, heart disease, and
migraine headaches. In order to look at how age may have
an effect on the health conditions we have classified the
findings into three age groups based on the age at the time
Table 6: Health problems of melanoma survivors: influence of treatment
All Melanoma Survivors Health Affected by Cancer
Surgery Alone Combined Treatments Surgery Alone Combined Treatments
n = 577 n = 391 n = 35 n = 117
n  ( % )n  ( % )n  ( % )n  ( % )
Arthritis/Osteoarthritis 101 (17.5%) 88 (22.5%) 8 (22.8%) 36 (30.7%)
Other/Subsequent Cancers 36 (6.2%) 76 (19.4%) 2 (5.7%) 30 (25.6%)
Cataracts 74 (12.8%) 61 (15.6%) 3 (8.5%) 14 (11.9%)
Circulation Problems 42 (7.3%) 61 (15.6%) 8 (22.8%) 30 (25.6%)
Hearing Problems 50 (8.6%) 54 (13.8%) 3 (8.5%) 17 (14.5%)
Loss of Memory 8 (1.4%) 42 (10.7%) 1 (2.8%) 23 (19.6%)
Skin Problems 34 (5.8%) 43 (10.9%) 2 (5.7%) 20 (17.1%)
Thyroid Problems 29 (5.1%) 29 (7.4%) 5 (14.3%) 12 (10.3%)
Abdominal Pain 14 (2.4%) 23 (5.8%) 3 (8.5%) 15 (12.8%)
Heart Problems 61 (10.6%) 46 (11.7%) 1 (2.8%) 13 (11.1%)BMC Cancer 2006, 6:95 http://www.biomedcentral.com/1471-2407/6/95
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of survey. In addition, we have broken down the findings
by type of treatment, combined treatment and surgery
alone, in order to assess how treatment may have played
a role in the survivors' lingering health effects. (Table 10)
Overall, melanoma survivors younger than 45 years at the
time of the survey reported higher rates of arthritis
(14.5%) and heart disease (10.8%) than age-matched
responders in the NHIS (7.8% and 4.0%, respectively).
Melanoma survivors between 45 and 64 years at the time
Table 8: Family relationships of melanoma survivors
Health Affected Health Not Affected
n (%) n (%)
Combined:
Treatment:
Improved Family Relationships 61 (31.6) 132 (68.4)
No Improvement 50 (31.1) 111 (68.9)
Hurt Family Relationships 18 (66.7) 9 (33.3)
No Harm 94 (27.6) 246 (72.4)
Improved Intimate Relationships 29 (32.2) 61 (67.8)
No Improvement 78 (31.8) 167 (68.2)
Hurt Intimate Relationships 38 (65.5) 20 (34.5)
No Harm 70 (24.1) 220 (75.9)
Surgery Alone:
Improved Family Relationships 11 (4.5) 231 (95.5)
No Improvement 24 (8.4) 260 (91.6)
Hurt Family Relationships 8 (42.1) 11 (57.9)
No Harm 24 (4.5) 504 (95.5)
Improved Intimate Relationships 5 (4.2) 113 (95.8)
No Improvement 29 (7.5) 356 (92.5)
Hurt Intimate Relationships 9 (36.0) 19 (64.0)
No Harm 22 (4.5) 465 (95.5)
Table 7: Association between time since diagnosis and health problems for melanoma survivors who had undergone combined 
treatments
Time Between Diagnosis and Survey
< 10 yrs n = 78 10–20 yrs n = 128 > 20 yrs n = 185
Health Problems n (%) n (%) n (%)
Arthritis/osteoarthritis 15 (19.2) 29 (22.6) 44 (23.7)
Hearing problems 8 (10.3) 20 (15.6) 26 (14.1)
Cataracts 5 (6.4) 17 (13.3) 39 (21.1)
Circulation problems 11 (14.1) 21 (16.4) 29 (15.6)
Heart problems 3 (3.8) 18 (14.1) 28 (15.1)
Skin problems 12 (15.4) 13 (10.2) 18 (9.7)
Loss of memory 13 (16.6) 12 (9.4) 17 (9.2)
Thyroid 6 (7.8) 11 (8.6) 12 (6.5)
Kidney problems 6 (7.8) 6 (4.7) 17 (9.2)
Abdominal pain 7 (8.9) 7 (5.5) 9 (4.8)BMC Cancer 2006, 6:95 http://www.biomedcentral.com/1471-2407/6/95
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of the survey indicated more kidney problems than their
age-matched NHIS responders (3.7% vs. 1.5%). Survivors
older than 65 years of age reported more health problems
than their age-matched NHIS counterparts (33.6% vs.
26.2%).
After combined treatment, melanoma survivors reported
more heart problems than their NHIS counterparts across
all three age groups, 14.3% vs. 4.0% for responders
younger than 45 years of age at the time of survey; 19.8%
vs. 12.7% for the 45–64 years of age group; and 43.9% vs.
26.2% for the older group.
After surgery alone, melanoma survivors indicated more
kidney problems than their age-matched NHIS counter-
parts across all three age groups, 5.7% vs. 0.6% for the
younger group; 3.7% vs. 1.5% for the 45–64 years of age
group, and 7.1% vs. 2.3% for the older group.
Discussion
Our descriptive analysis indicates that, overall, melanoma
survivors report relatively few lasting medical or social
problems, even after often intensive combination treat-
ment. However, age, gender, treatment, and several phys-
iologic and psychological factors influence melanoma
survivor's health profiles.
This study has several limitations. It is a subset of a larger
cohort, and survey questions were not specific to
melanoma survivors. In addition, the information
includes self-reported problems that were only partly ver-
ifiable through medical record reviews, a limitation
shared by the NHIS methodology. Nevertheless, the
melanoma survivors answered the same questions as
more than 10,000 survivors of other cancers, allowing for
the opportunity to compare the health profiles of
melanoma survivors with those of other cancer survivors,
as well as NHIS responders.
Study of the long-term health outcomes of cancer survi-
vors was conducted the earliest and most comprehen-
sively in children [12-15]. Several investigators have noted
that survivors of adult cancers experience significant lin-
gering effects that influence their quality of life [16,17]
and physiological health for many years [18]. Breast can-
cer survivors, for example, reported poorer functioning
especially after chemotherapy [19]. In this group, prior
chemotherapy was also identified as a risk factor for heart
disease [20], the role of chest irradiation in the develop-
ment of heart disease is less clear [21]. The symptoms and
perceived problems often vary with the underlying malig-
nancy [22]. Survivors of Hodgkin's disease have been
found to have a higher rate of early mortality related to
second primary cancers, heart disease, and infections than
do those who have not had cancer [23]. Patients with tes-
ticular cancer fair well overall, both physiologically and
psychologically, but they experience a number of lasting
health problems [24-26]. In addition, researchers have
characterized the late effects of chemotherapy and radia-
tion on the pulmonary [27], circulatory [28], and cardiac
[29,30] systems. Reports on melanoma are uncommon
and limited to older feasibility studies [31] or case reports
[32]. Close, life-long medical surveillance has been rec-
ommended [8] especially for patients with choroidal
melanoma, who may have more quality of life problems
[33,34].
In the present report, we used information obtained
through a comprehensive survey of cancer survivors to
determine the medical/physiologic and psychosocial
characteristics and problems that affect long-term
melanoma survivors.
In general, melanoma survivors reported fewer long-term
health problems than did survivors of other cancers; this
was particularly the case when they had been treated with
surgery alone. In addition, they were less likely than survi-
vors of other cancers to report that cancer had affected
their overall health, although this response was found
Table 9: Relationship between treatments and health problems
Treatment Number of Patients* Most Frequently Reported Health Effects
Dacarbazine 89 Cardiovascular (12%), lymphedema (8%), arthritis (4%)
Phenylalanine mustard 65 Cardiovascular (10%), lymphedema (11%), arthritis (5%)
Radiation therapy 63 Radiation damage (8%), cardiovascular (8%), diabetes (5%)
Interferon 52 Cardiovascular (6%), skin problems (6%), lymphedema (4%)
Bacillus Calmette-Guerin 42 Cardiovascular (14%), lymphedema (12%), ulcer problems (5%)
Cisplatin 31 Arthritis (6%), cardiovascular (6%), neuropathy (6%)
Actinomycin-D 22 Cardiovascular (36%), lymphedema (14%), arthritis (9%)
Vinblastine 21 Neuropathy (9%), arthritis (5%),
Interleukin 18 Arthritis (6%), cardiovascular (6%),
Vincristine 17 Cardiovascular (18%),
* A few patients received more than one agent.BMC Cancer 2006, 6:95 http://www.biomedcentral.com/1471-2407/6/95
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more frequently among those who had undergone com-
bined treatment than surgery alone. Patients who believed
cancer affected their overall health also believed cancer
hurt their family and intimate relationships. As a group,
melanoma survivors were younger than survivors of other
cancers, and younger age at the time of diagnosis tends to
correlate with increased distress from the cancer experi-
ence in survivors of other cancers, [2] but this was not
obvious in this cohort. Systematic, prospective analyses of
patients diagnosed with melanoma will be very important
in order to define the long-term impact of this disease.
Conclusion
Long-term melanoma survivors generally report that can-
cer had relatively little lasting effects on their health,
although a number of disease-related and psychosocial
factors influence their perception.
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Table 10: Health status of melanoma survivors versus that of NHIS participants
A. Overall
< 45 Survivors* n 
= 83
< 45 NHIS1 n = 
108114
45–64 Survivors* 
n = 405
45–64 NHIS1 n = 
64650
≥ 65 Survivors* n 
= 508
≥ 65 NHIS1 n = 
17809
Arthritis 14.4% 7.8% 16.1% 28.8% 23.2% 44.6%
Diabetes Mellitus 2.4% 1.9% 3.5% 9.3% 10.0% 17.1%
Hearing Loss 2.4% 6.7% 3.7% 17.5% 18.1% 29.7%
Heart Disease 10.8% 4.0% 16.1% 12.7% 33.6% 26.2%
Kidney Problems 3.6% 0.6% 3.7% 1.5% 8.5% 2.3%
Liver Problems 2.4% 0.8% 1.2% 1.9% 0.9% 1.3%
Migraine 
Headaches
3.6% 17.6% 3.5% 15.3% 0.7% 7.8%
B. Combined Treatments
< 45 Survivors* n 
= 28
< 45 NHIS1 n = 
108114
45–64 Survivors* 
n = 156
45–64 NHIS1 n = 
64650
≥ 65 Survivors* n 
= 207
≥ 65 NHIS1 n = 
17809
Arthritis 21.4% 7.8% 19.2% 28.8% 25.1% 44.6%
Diabetes Mellitus 3.7% 1.9% 2.5% 9.3% 10.6% 17.1%
Hearing Loss 7.2% 6.7% 4.5% 17.5% 21.7% 29.7%
Heart Disease 14.3% 4.0% 19.8% 12.7% 43.9% 26.2%
Kidney Problems 0.0% 0.6% 3.8% 1.5% 11.1% 2.3%
Liver Problems 0.0% 0.8% 2.5% 1.9% 2.4% 1.3%
Migraine 
Headaches
7.2% 17.6% 4.5% 15.3% 0.5% 7.8%
C. Surgery Alone
< 45 Survivors* n 
= 53
< 45 NHIS1 n = 
108114
45–64 Survivors* 
n = 240
45–64 NHIS1 n = 
64650
≥ 65 Survivors* n 
= 284
≥ 65 NHIS1 n = 
17809
Arthritis 11.3% 7.8% 13.7% 28.8% 21.8% 44.6%
Diabetes Mellitus 1.9% 1.9% 4.2% 9.3% 9.8% 17.1%
Hearing Loss 0.0% 6.7% 2.9% 17.5% 15.1% 29.7%
Heart Disease 9.4% 4.0% 13.3% 12.7% 27.1% 26.2%
Kidney Problems 5.7% 0.6% 3.7% 1.5% 7.1% 2.3%
Liver Problems 3.8% 0.8% 0.4% 1.9% 0.0% 1.3%
Migraine 
Headaches
1.9% 17.6% 2.9% 15.3% 1.1% 7.8%
* At time of survey
1 NHIS data from Vital and Health Statistics Series 10, Number 222. National Health Interview Survey, US Department of Health and 
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